N
AH

Natixis’s Accretive Health AH Stock Holding History

Natixis’s Portfolio AH Stock Details AH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-46,758
Closed -$374K – 583
2014
Q1 		$374K Buy
46,758
+35,070
+300% +$311K ﹤0.01% 391
2013
Q4 		$107K Sell
11,688
-8,388
-42% -$72.2K ﹤0.01% 497
2013
Q3 		$183K Sell
20,076
-3,749
-16% -$37.3K ﹤0.01% 417
2013
Q2 		$258K Buy
+23,825
New +$251K ﹤0.01% 380

Other funds holding AH

JRP
Jasper Ridge Partners Menlo Park, California $4.69B AUM 31.34% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
RMC
Regis Management Company Menlo Park, California $331M AUM 14.13% 1-Year Est. Return
BCM
Breithorn Capital Management New York $141M AUM 41.82% 1-Year Est. Return
ECM
EII Capital Management New York $774K AUM 22.41% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
MIM
Merion Investment Management Bay Harbor Islands, Florida $1.26M AUM 28.57% 1-Year Est. Return
PCMI
Paradigm Capital Management Inc Albany, New York $3.67B AUM 121.12% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
SCM
Stonebridge Capital Management Los Angeles, California $208M AUM

Natixis's AH Position: Q2 2014 in Review

Natixis sold out of Accretive Health (AH) in Q2 2014, closing a stake of 46,758 shares — an estimated $374K sold.

Natixis first reported a position in AH in Q2 2013 and held it in 4 quarters. The position peaked at $374K in Q1 2014. 12 funds tracked by Wall St. Rank hold AH as of Q2 2014.

  • Natixis reported no remaining Accretive Health position as of Q2 2014 after selling out during the quarter.
  • Natixis sold 46,758 Accretive Health shares in Q2 2014, an estimated $374K.
  • Natixis first reported a position in Accretive Health in Q2 2013 and held it in 4 quarters.
  • Natixis's Accretive Health position peaked at $374K in Q1 2014.
  • 12 funds tracked by Wall St. Rank held Accretive Health as of Q2 2014.

Based on Natixis's 13F filing for Q2 2014, filed 14 Aug 2014.